Odds of testing positive for SARS-CoV-2 were 22 percent higher in patients who were overweight
Every 1 kg/m2 rise in a patient s BMI was associated with an increase of around 2 percent in the risk of testing positive for SARS-CoV-2
Jerusalem: People with increasing body mass index (BMI) may be at a higher risk of testing positive for SARS-CoV-2, the virus which causes COVID-19, finds a new study.
The researchers, from the Chaim Sheba Medical Centre in Israel, found that the odds of testing positive for SARS-CoV-2 were 22 percent higher in patients who were overweight or obese compared to those with a normal BMI.
Inflammasomes May Play a Role in Obesity-Related CRC
medscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medscape.com Daily Mail and Mail on Sunday newspapers.
Share
Half were given the jab and half a placebo.
They completed surveys on their eating habits and appetite at the start of the trial and again after 20 weeks. They had a set breakfast, followed by an unlimited lunch five hours later.
Patients on the drug ate 1,736 calories at lunch, which was 940 fewer than those on the placebo.
Those given the jab lost 9.9 per cent of their body weight on average, compared with 0.4 per cent in those on the dummy drug.
Patients on the medication reported a smaller appetite and better hunger control during the study.
The jab is available at a dose of 1mg to treat type 2 diabetes but the trial used 2.4mg.
E-Mail
New research presented at this year s European Congress on Obesity (held online, 10-13 May) shows that the obesity drug semaglutide reduces appetite, food cravings and energy intake in people given a meal where they could eat as much as they liked. The study is by Dr Dorthe Skovgaard, Novo Nordisk A/S (the manufacturer of the drug), Søborg, Denmark, and colleagues.
Semaglutide, in the glucagon-like peptide-1 (GLP-1) analogue drug class, is currently available at the dose of 1.0 mg injected once weekly for the treatment of type 2 diabetes and is under development for chronic weight management at the dose 2.4 mg injected once weekly. It is currently not approved for obesity anywhere in the world, however new drug applications are under review by the US Food and Drug Administration (FDA), the European Medicines Agency (EMA), and other health agencies across the world.
People who are overweight are 22% more likely to catch Covid virus
That figure increased to 27% for those considered obese
SIGN UP
When you subscribe we will use the information you provide to send you these newsletters. Your information will be used in accordance with ourPrivacy Notice.
Thank you for subscribingWe have more newslettersShow meSee ourprivacy notice
People with a higher body mass index (BMI) are more likely to test positive for the virus that causes Covid-19, new research suggests.
A study by the Chaim Sheba Medical Centre in Israel found that patients who are classed as overweight – with a BMI of 25 to 29.9 – were 22% more likely to contract the virus than someone of “normal” weight with a BMI of 18.5 to 24.9.
vimarsana © 2020. All Rights Reserved.